All News
The Increasing Cost of First-Line Biologics for Plaque Psoriasis
A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125).
Read Article
Genetic Analysis of Asymptomatic Antinuclear Antibody Positive Patients
A large scale genomic population study found antinuclear antibodies (ANA) in up to 14% of the population; most with ANA are asymptomatic, and ANA production is not associated with significant genetic risk.
Genomics and Future Drug Targets for Osteoarthritis
d
EurekAlert!
A Nature article details the results of an osteoarthritis, genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported.
Read Article
Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Sponsored by Amgen
https://t.co/N6C0mxJ7Td https://t.co/gD7aI26wh9
Dr. John Cush RheumNow ( View Tweet)
Distinguishing Septic and Gouty Arthritis
A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal threshold of 50,000 https://t.co/00kNogjRdr
Dr. John Cush RheumNow ( View Tweet)
Predictors of Developing RA
A prospective cohort study of seropositive arthralgia patients demonstrated that baseline characteristics and labs can be used to predict which arthralgia patients are at highest risk of developing RA. These studies underscore the influence of https://t.co/WAohoaiBwY
Dr. John Cush RheumNow ( View Tweet)
Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutations & loss of functional sclerostin. Results in high bone mass & skeletal overgrowth (Sxs of facial paralysis, hearing loss, incr intracranial pressure https://t.co/9DYO82quiC
Dr. John Cush RheumNow ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush RheumNow ( View Tweet)
Ultrasound lesions of dactylitis associ w/short-term development of PsA. Study of 64 PsO +arthralgia pts. IUS PD synovitis & B mode enthesitis predicted PsA Dx (p < .001) w/ an accuracy of 89.1 %, a sensitivity of 86.7 % and a specificity of 89.8 %. https://t.co/Ij6oYP1TuK https://t.co/55sO4uFXNI
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/CQn9EVjr9g https://t.co/vVnTo2FPV6
Dr. John Cush RheumNow ( View Tweet)
AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/u8abvqNtnX
Dr. John Cush RheumNow ( View Tweet)
Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 developed KOA. HRs for incident KOA were 0.84 (0.76-0.92), 0.81 (0.71-0.90), and 0.74 (0.64-0.85) if walking ~5000, ~7000, & ≥8000 steps/d, respectively https://t.co/St9QLuOy9R
Dr. John Cush RheumNow ( View Tweet)
Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and boosts remission rates without background immunosuppressants. CD19+ B-cell depletion shows promise as a new treatment. #Rheum @RheumNow https://t.co/7iSyPfnMV0 https://t.co/M51b0dipMs
Links:
Natasha Salman, DO DrNatashaSalman ( View Tweet)
✅ T2T in #Lupus 👀 ⬇️⬇️
📥 LINK https://t.co/F8w8qRZdsS
#NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4
Links:
Laurent ARNAUD Lupusreference ( View Tweet)
Our Chief Medical Editor Leonard H. Calabrese, DO, (@LCalabreseDO) shares his reflections on the book: Masterclass in Medicine: Lessons from the Experts
@ClevelandClinic
https://t.co/gZhbrBLcnR
Healio Rheumatology HealioRheum ( View Tweet)
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/uLoRmsAkiG https://t.co/ExthuSBSXs
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 is now available On Demand
For the first time, https://t.co/4UQlqwujiR is offering exclusive access to:
✅ 7 STEP Talks from top rheumatology experts
✅ 21 Powerful lectures and Q & A Panels answering real-world questions
✅ All speaker slides and handouts https://t.co/saW9WH4djO
Links:
Dr. John Cush RheumNow ( View Tweet)
In a murine model of Kawasaki Dz vasculitis- depleting gut microbiota reduces KD like vasculitis. CV lesions were assoc w/ decrease in Akkermansia muciniphila and Faecalibacterium prausnitzii. Replacement attenuated these findings. https://t.co/Hnij8TWkYy https://t.co/wEuVcuAZ5j
Dr. John Cush RheumNow ( View Tweet)
Systematic review of >90 studies on Pregnancy and RA risk indicates that parity, gravidity, infertility, pregnancy loss do not adversely affect RA development. But low birthweight was assoc w/ RA Dx/severity, and pre-eclampsia incr risk of subsequent RA Dx. https://t.co/jVa4tmSqvj
Dr. John Cush RheumNow ( View Tweet)